Fifth Third Bancorp Lowers Position in Qiagen (NYSE:QGEN)

Fifth Third Bancorp decreased its stake in Qiagen (NYSE:QGEN) by 19.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,874 shares of the company’s stock after selling 15,060 shares during the quarter. Fifth Third Bancorp’s holdings in Qiagen were worth $2,800,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. State Street Corp increased its holdings in Qiagen by 3.9% in the 3rd quarter. State Street Corp now owns 2,380,008 shares of the company’s stock worth $108,457,000 after acquiring an additional 90,181 shares in the last quarter. Jennison Associates LLC increased its holdings in Qiagen by 5.0% in the 3rd quarter. Jennison Associates LLC now owns 1,426,392 shares of the company’s stock valued at $65,001,000 after acquiring an additional 68,415 shares during the last quarter. XTX Topco Ltd lifted its stake in Qiagen by 129.3% in the 3rd quarter. XTX Topco Ltd now owns 20,192 shares of the company’s stock worth $920,000 after purchasing an additional 11,385 shares in the last quarter. Sanctuary Advisors LLC boosted its holdings in shares of Qiagen by 24.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company’s stock valued at $834,000 after purchasing an additional 3,878 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Qiagen by 36.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock worth $73,096,000 after acquiring an additional 424,937 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

Qiagen stock opened at $45.49 on Tuesday. Qiagen has a 1-year low of $39.03 and a 1-year high of $47.93. The company’s 50-day moving average is $44.69 and its 200 day moving average is $44.35. The firm has a market capitalization of $10.38 billion, a P/E ratio of 116.63, a price-to-earnings-growth ratio of 3.49 and a beta of 0.37. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89.

Wall Street Analyst Weigh In

QGEN has been the subject of a number of research reports. Jefferies Financial Group reiterated a “buy” rating and set a $54.00 target price (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Morgan Stanley restated an “equal weight” rating and set a $48.00 target price (down from $50.00) on shares of Qiagen in a research report on Monday, January 6th. Finally, HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a research report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $51.50.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.